IL284448B2 - העברה פסיבית של חסינות באמצעות וקטורי תרכיב וירוס 2 הרפס סימפלקס רקומביננטי - Google Patents
העברה פסיבית של חסינות באמצעות וקטורי תרכיב וירוס 2 הרפס סימפלקס רקומביננטיInfo
- Publication number
- IL284448B2 IL284448B2 IL284448A IL28444821A IL284448B2 IL 284448 B2 IL284448 B2 IL 284448B2 IL 284448 A IL284448 A IL 284448A IL 28444821 A IL28444821 A IL 28444821A IL 284448 B2 IL284448 B2 IL 284448B2
- Authority
- IL
- Israel
- Prior art keywords
- hsv
- subject
- glycoprotein
- infection
- mice
- Prior art date
Links
- 241000701074 Human alphaherpesvirus 2 Species 0.000 title claims description 533
- 238000012546 transfer Methods 0.000 title claims description 15
- 229960005486 vaccine Drugs 0.000 title description 72
- 230000036039 immunity Effects 0.000 title description 6
- 239000013598 vector Substances 0.000 title description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 182
- 108090000623 proteins and genes Proteins 0.000 claims description 88
- 208000015181 infectious disease Diseases 0.000 claims description 76
- 102000003886 Glycoproteins Human genes 0.000 claims description 67
- 108090000288 Glycoproteins Proteins 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 63
- 238000012217 deletion Methods 0.000 claims description 56
- 230000037430 deletion Effects 0.000 claims description 56
- 230000003612 virological effect Effects 0.000 claims description 48
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims description 41
- 210000002966 serum Anatomy 0.000 claims description 38
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims description 37
- 230000003053 immunization Effects 0.000 claims description 35
- 238000002649 immunization Methods 0.000 claims description 28
- 230000028993 immune response Effects 0.000 claims description 27
- 208000037952 HSV-1 infection Diseases 0.000 claims description 23
- 230000003472 neutralizing effect Effects 0.000 claims description 19
- 230000001902 propagating effect Effects 0.000 claims description 10
- 208000009889 Herpes Simplex Diseases 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000000568 immunological adjuvant Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229940088592 immunologic factor Drugs 0.000 claims description 3
- 239000000367 immunologic factor Substances 0.000 claims description 3
- 102000009490 IgG Receptors Human genes 0.000 claims 2
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 description 171
- 210000004027 cell Anatomy 0.000 description 132
- 210000002845 virion Anatomy 0.000 description 72
- 241000700584 Simplexvirus Species 0.000 description 52
- 241000700605 Viruses Species 0.000 description 49
- 210000003491 skin Anatomy 0.000 description 48
- 208000003322 Coinfection Diseases 0.000 description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 45
- 201000010099 disease Diseases 0.000 description 44
- 239000000203 mixture Substances 0.000 description 42
- 239000008194 pharmaceutical composition Substances 0.000 description 31
- 239000000232 Lipid Bilayer Substances 0.000 description 30
- 210000003501 vero cell Anatomy 0.000 description 28
- 239000000427 antigen Substances 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 27
- 239000013592 cell lysate Substances 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 23
- 150000007523 nucleic acids Chemical class 0.000 description 23
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 22
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 22
- 108020004707 nucleic acids Proteins 0.000 description 22
- 102000039446 nucleic acids Human genes 0.000 description 22
- 210000001744 T-lymphocyte Anatomy 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 19
- 102000004127 Cytokines Human genes 0.000 description 18
- 108090000695 Cytokines Proteins 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 18
- 241000725303 Human immunodeficiency virus Species 0.000 description 17
- 239000006166 lysate Substances 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 230000008774 maternal effect Effects 0.000 description 14
- 238000011740 C57BL/6 mouse Methods 0.000 description 12
- 101900228213 Human herpesvirus 2 Envelope glycoprotein D Proteins 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 239000011324 bead Substances 0.000 description 12
- 244000052769 pathogen Species 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 210000003594 spinal ganglia Anatomy 0.000 description 11
- 241001529936 Murinae Species 0.000 description 10
- 108700019146 Transgenes Proteins 0.000 description 10
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 210000004392 genitalia Anatomy 0.000 description 10
- 231100000518 lethal Toxicity 0.000 description 10
- 230000001665 lethal effect Effects 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 238000003753 real-time PCR Methods 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 230000003622 anti-hsv Effects 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 239000012636 effector Substances 0.000 description 9
- 210000003754 fetus Anatomy 0.000 description 9
- 210000004251 human milk Anatomy 0.000 description 9
- 235000020256 human milk Nutrition 0.000 description 9
- 238000007390 skin biopsy Methods 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 9
- 210000002865 immune cell Anatomy 0.000 description 8
- 210000001165 lymph node Anatomy 0.000 description 8
- 230000001018 virulence Effects 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000000644 propagated effect Effects 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 6
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 6
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 6
- 108020005202 Viral DNA Proteins 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 244000045947 parasite Species 0.000 description 6
- 230000009984 peri-natal effect Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 210000000427 trigeminal ganglion Anatomy 0.000 description 6
- 201000008827 tuberculosis Diseases 0.000 description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 208000001688 Herpes Genitalis Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 201000004946 genital herpes Diseases 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 230000001296 transplacental effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 4
- 206010015548 Euthanasia Diseases 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 4
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 4
- 241000186362 Mycobacterium leprae Species 0.000 description 4
- 241000187492 Mycobacterium marinum Species 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 210000005000 reproductive tract Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 229940031626 subunit vaccine Drugs 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 241000606161 Chlamydia Species 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 241000711950 Filoviridae Species 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 241000187917 Mycobacterium ulcerans Species 0.000 description 3
- 241000588653 Neisseria Species 0.000 description 3
- 208000020241 Neonatal disease Diseases 0.000 description 3
- 208000037129 Newborn Diseases Infant Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 241000713112 Orthobunyavirus Species 0.000 description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 3
- 101710186352 Probable membrane antigen 3 Proteins 0.000 description 3
- 101710181078 Probable membrane antigen 75 Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 101710178472 Tegument protein Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 101150036031 gD gene Proteins 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000007420 reactivation Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 241000867607 Chlorocebus sabaeus Species 0.000 description 2
- 206010010099 Combined immunodeficiency Diseases 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 101710187780 Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000005551 perinatal transmission Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003699 striated muscle Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000012117 Alexa Fluor 700 Substances 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 208000037018 Herpes simplex virus encephalitis Diseases 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000007993 Kaposi Varicelliform Eruption Diseases 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 102000002356 Nectin Human genes 0.000 description 1
- 108060005251 Nectin Proteins 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000144282 Sigmodon Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- PVNJLUVGTFULAE-UHFFFAOYSA-N [NH4+].[Cl-].[K] Chemical compound [NH4+].[Cl-].[K] PVNJLUVGTFULAE-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 238000011198 co-culture assay Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000011304 droplet digital PCR Methods 0.000 description 1
- 206010014197 eczema herpeticum Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 230000006450 immune cell response Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 210000004964 innate lymphoid cell Anatomy 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229940021686 isothesia Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000007485 viral shedding Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/844—Liver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/238,933 US10918712B2 (en) | 2014-03-03 | 2019-01-03 | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors |
| PCT/US2020/012170 WO2020142677A1 (en) | 2019-01-03 | 2020-01-03 | Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL284448A IL284448A (he) | 2021-08-31 |
| IL284448B1 IL284448B1 (he) | 2023-08-01 |
| IL284448B2 true IL284448B2 (he) | 2023-12-01 |
Family
ID=69400650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284448A IL284448B2 (he) | 2019-01-03 | 2020-01-03 | העברה פסיבית של חסינות באמצעות וקטורי תרכיב וירוס 2 הרפס סימפלקס רקומביננטי |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3906052A1 (he) |
| JP (2) | JP2022517322A (he) |
| CN (1) | CN113727728A (he) |
| AU (1) | AU2020204688A1 (he) |
| CA (1) | CA3124523A1 (he) |
| IL (1) | IL284448B2 (he) |
| WO (1) | WO2020142677A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023245159A1 (en) * | 2022-06-16 | 2023-12-21 | Albert Einstein College Of Medicine | Recombinant herpes simplex virus 2 (hsv-2) vectors and engineered transgenic vero cell lines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110938604B (zh) * | 2014-03-03 | 2024-04-05 | 阿尔伯特爱因斯坦医学院 | 重组单纯疱疹病毒2(hsv-2)疫苗载体 |
| US10918712B2 (en) * | 2014-03-03 | 2021-02-16 | Albert Einstein College Of Medicine | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors |
| DE102014117280A1 (de) * | 2014-11-25 | 2016-05-25 | Pilz Gmbh & Co. Kg | Sicherheitsschaltgerät zum Ein- und sicheren Ausschalten eines elektrischen Verbrauchers |
-
2020
- 2020-01-03 IL IL284448A patent/IL284448B2/he unknown
- 2020-01-03 EP EP20702946.3A patent/EP3906052A1/en active Pending
- 2020-01-03 CA CA3124523A patent/CA3124523A1/en active Pending
- 2020-01-03 CN CN202080018414.0A patent/CN113727728A/zh active Pending
- 2020-01-03 AU AU2020204688A patent/AU2020204688A1/en active Pending
- 2020-01-03 WO PCT/US2020/012170 patent/WO2020142677A1/en unknown
- 2020-01-03 JP JP2021539019A patent/JP2022517322A/ja active Pending
-
2023
- 2023-10-12 JP JP2023176398A patent/JP2024016032A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3124523A1 (en) | 2020-07-09 |
| CN113727728A (zh) | 2021-11-30 |
| AU2020204688A1 (en) | 2021-07-15 |
| IL284448B1 (he) | 2023-08-01 |
| EP3906052A1 (en) | 2021-11-10 |
| KR20210112343A (ko) | 2021-09-14 |
| JP2024016032A (ja) | 2024-02-06 |
| IL284448A (he) | 2021-08-31 |
| WO2020142677A1 (en) | 2020-07-09 |
| JP2022517322A (ja) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10980874B2 (en) | Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors | |
| Petro et al. | Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease | |
| US8501194B2 (en) | Vaccine for viruses that cause persistent or latent infections | |
| US10918712B2 (en) | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors | |
| Kao et al. | Murine model of maternal immunization demonstrates protective role for antibodies that mediate antibody-dependent cellular cytotoxicity in protecting neonates from herpes simplex virus type 1 and type 2 | |
| Görander et al. | A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection | |
| JP2024016032A (ja) | 組み換え単純ヘルペスウイルス２（ｈｓｖ－２）ワクチンベクターを使用する免疫の受動伝達 | |
| Chung et al. | The ongoing pursuit of a prophylactic HSV vaccine | |
| US20220088185A1 (en) | Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors | |
| KR102686042B1 (ko) | 재조합 단순 헤르페스 바이러스 2 (hsv-2) 백신 벡터를 사용한 면역의 수동 전달 | |
| WO2023245159A1 (en) | Recombinant herpes simplex virus 2 (hsv-2) vectors and engineered transgenic vero cell lines | |
| Wang | CD4 (+) cytotoxic T lymphocyte activity against bovine herpesvirus type 1 infection |